Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Fineline Cube Jan 22, 2026
Company Deals

Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO

Fineline Cube May 16, 2024

Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic...

Company Medical Device

Lifetech Scientific’s IBS Stent Demonstrates Non-Inferiority in Phase II Trial

Fineline Cube May 16, 2024

Lifetech Scientific Corporation (HKG: 1302), a biopharmaceutical company based in China, has announced the completion...

Company Drug

Olymvax Biopharmaceuticals Gets Green Light for Tetravalent Influenza Vaccine Clinical Trial

Fineline Cube May 16, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...

Company Drug

Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors

Fineline Cube May 16, 2024

China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...

Company Deals Medical Device

GE HealthCare Partners with Shanghai Pudong for USD 52.5 Million Medical Tech Investment

Fineline Cube May 16, 2024

GE HealthCare (NASDAQ: GEHC), a leading medical technology firm, has entered into a cooperation intent...

Company Deals Medical Device

Vision Medicals Raises Hundreds of Millions in Series D+ Round to Advance Molecular Diagnostics

Fineline Cube May 16, 2024

Guangdong-based Vision Medicals has reportedly secured hundreds of millions of renminbi in a Series D+...

Company Deals

Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets

Fineline Cube May 16, 2024

Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ:...

Company Deals Hospital

Eli Lilly & Co. Expands Clinical Collaboration with Shanghai East Hospital in China

Fineline Cube May 16, 2024

Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion...

Company Drug

Everest Medicines Commences Commercial Sales of Nefecon in China Post-Launch

Fineline Cube May 15, 2024

Everest Medicines (HKG: 1952), a leading pharmaceutical company based in China, has announced the official...

Company Deals

Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round

Fineline Cube May 15, 2024

China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in...

Company Policy / Regulatory

US Readies Hefty Tariffs on Chinese Medical Equipment and Other Imports

Fineline Cube May 15, 2024

The US Office of the Trade Representative (USTR) has announced a series of stringent new...

Company

Genmab CEO Cites China’s Biotech as a ‘Mind-Boggling’ Source of Innovation

Fineline Cube May 15, 2024

Jan van de Winkel, CEO of Denmark-based biotech Genmab (NASDAQ: GMAB), has expressed optimism about...

Company Drug

Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod

Fineline Cube May 15, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...

Company Drug

Zai Lab Advances Vygart Hytrulo for CIDP with sBLA Filing in China

Fineline Cube May 15, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, has announced...

Company Drug

Jiangsu Hengrui’s SHR-2173 Gets Green Light for Clinical Trial in IgA Nephropathy

Fineline Cube May 15, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

ViiV Healthcare’s HIV-PreP Therapy Approved by China’s NMPA, Offers Alternative to Daily Medication

Fineline Cube May 15, 2024

GlaxoSmithKline’s (GSK; NYSE: GSK) subsidiary, ViiV Healthcare, has announced that it has received marketing approvals...

Company Drug

Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar

Fineline Cube May 15, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the...

Policy / Regulatory

China Launches Nationwide Unannounced Inspections of Medical Insurance Funds

Fineline Cube May 15, 2024

An inaugural meeting for the first batch of unannounced medical insurance fund inspections was conducted...

Company Drug

Novo Nordisk’s Wegovy Shows Durable Weight Loss and Heart Health in Extended Trials

Fineline Cube May 15, 2024

At the 31st European Congress on Obesity (ECO), Denmark’s pharmaceutical giant Novo Nordisk (CPH: NOVO-B)...

Company Drug

RemeGen’s Telitacicept Achieves Full Enrollment in Phase III Primary Sjogren’s Syndrome Trial

Fineline Cube May 15, 2024

China-based pharmaceutical company RemeGen (HKG: 9995) has announced the completion of patient enrollment in a...

Posts pagination

1 … 306 307 308 … 612

Recent updates

  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
  • AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.